quest for a doc


New member
while takin fina and test prop, should my bull wear a condom while banging the cow? dont want the cow to get a shot of vitamine "T" thx!
After about 1 week your bull should be shotting blanks, but every bull is different. If Trojan makes one big enough, I would wear one to be sure.
AS will reduce FSH which usually leads to oligospermia (low sperm count)...
Azoospermia (complete absence of sperm in the semen) is sometimes achieved, but it's rare so your bull should definately wear a condom ..
not worried about swimmers bulls been fixed! dont want the cow to get a shot of test from the nut drizzle! is this even possible?
as long as your feed lot heifer isnt due for slaughter soon...she should be ok with any transfluid transfer of hormones....just make sure none of her byproducts, nor consumable excretions are consumed by humans at least 2 weeks after bovine copulation
Do you know what they call guys who think steroids are a form of birth control? Yup: Dad!
I thought one of the indications of Testosterone were for oligospermia.
I always thought that steroids lowered your sperm count, but then on the other side, the pamphlet says Testosterone is used to treat oligospermia??? what's up?
AS do lower your sperm count since they lower FSH which is essential for spermatogenesis...
According to the info I've seen test was actually used to suppress sperm production in hope that sperm rebound would occur after test administration is stopped.
It's rarely used for that purpose.

Here's some info:

This is given to suppress sperm production in the hope that when medication is stopped (usually after 5-6 months), then the sperm production will "rebound " to higher levels than originally (testosterone rebound). This form of treatment is now seldom used as it may further impair fertility and is hazardous. Testosterone is also be used for the treatment of impotence or diminished libido when blood testosterone levels are low. Testosterone is available as an oily injection and is given intramuscularly, usually once a week. Oral preparations are also available now, but these are more expensive and may not be as effective.
Cochrane Database Syst Rev 2000;(2):CD000150 Related Articles, Links

Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.

Vandekerckhove P, Lilford R, Vail A, Hughes E.

Institute of Epidemiology, University of Leeds, 34 Hyde Terrace, Leeds, Yorkshire, UK, LS2 9LN.

BACKGROUND: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology) of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility. Androgens have been suggested as a treatment because its binding proteins maintain a maintain a high intratesticular level testosterone essential for spermatogenesis and because the epididymis and seminal vesicles affect the seminal constitution and sperm motility and are also androgen-dependent. However exogenous testosterone was found to exert negative feedback on the pituitary-gonadal axis and thereby to suppress FSH and LH secretion. Spermatogenesis was thus adversely affected. Nevertheless androgens are used for the treatment of male infertility either for a putative direct "stimulatory" or "rebound" therapy. The stimulatory androgens used are mesterolone and testosterone undecanoate which, it is postulated, in a form and dosage that does not influence pituitary gonadotrophin secretion, either have a direct stimulatory effect on spermatogenesis or influence sperm transport and maturation though an effect on the epididymis, ductus deferens and seminal vesicles. Other androgens have been used to produce a rebound effect. These androgens are administered to suppress gonadotrophin secretion and spermatogenesis. After androgen therapy is discontinued there is a surge of FSH and LH and spermatogenesis is recommenced. Because of their different proposed mechanisms of action, stimulatory and rebound androgen therapy are analysed separately in the comparisons. This review considers the available evidence of the effect of androgens for idiopathic oligo and/or asthenospermia. OBJECTIVES: The objective of this review was to assess the effect of androgen treatment of men among couples where failure to conceive has been attributed to idiopathic oligo- and/or asthenospermia. SEARCH STRATEGY: The Cochrane Subfertility Review Group specialised register of controlled trials was searched". SELECTION CRITERIA: Randomised trials of mesterolone or testosterone undecanoate versus placebo or no treatment (stimulatory therapy), or testosterone enanthate or testosterone undecanoate versus placebo or no treatment (rebound therapy) in couples where subfertility is attributed to male factor. DATA COLLECTION AND ANALYSIS: Eligibility and trial quality were assessed. MAIN RESULTS: Eleven trials involving 930 patients were included. For stimulatory therapy, androgens had little effect on endocrinal outcomes and sperm parameters. The rate of pregnancy after androgens with stimulatory effect compared to no treatment or placebo was also similar (odds ratio 1.10, 95% confidence interval 0.75 to 1.61). In rebound therapy, no difference was found in sperm parameters. The pregnancy rate after androgens with rebound effect also showed no difference compared to no treatment or placebo (odds ratio 1.60, 95% confidence interval 0.42 to 6.16). Adverse effects such as headaches and exanthema were reported. REVIEWER'S CONCLUSIONS: There is not enough evidence to evaluate the use of androgens for male subfertility. [This abstract has been prepared centrally.]